From Globe Newswire: 2024-03-28 07:05:00

Xilio Therapeutics is making strategic changes to focus on advancing clinical-stage programs for tumor-activated immuno-oncology therapies. They have announced additional Phase 2 data for XTX202 and an exclusive license agreement with Gilead Sciences. Xilio is anticipating a cash runway into Q2 2025 and has entered into a private placement agreement to issue and sell shares of common stock to existing investors. The company also plans to reprioritize resources and streamline operations, including a reduction in headcount. Xilio will host a conference call today at 8:00 a.m. ET to discuss these developments.



Read more at Globe Newswire: Xilio Therapeutics Announces $11.3 Million Private